Does Bevacizumab Work with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma?

Results of a recent study in England showed that adding bevacizumab to conventional radiotherapy and temozolomide chemotherapy in newly diagnosed glioblastoma did not affect overall survival. It did, however, provide some benefit in disease progression, quality of life and cognitive function.
Glioblastoma is the most common and most aggressive brain tumor. It generally occurs between ages 40-60 and is slightly more common in men than women. Average survival after diagnosis is 14 months. It is also an insidious tumor: patients who otherwise seem well may seek care with only a headache or a minor seizure and discover they have the disease. Its short survival and profound effects on patients and those around them make glioblastoma a very serious disease and formidable enemy. As many tools as possible are needed to confront such an aggressive disease. Intensive research therefore continues into treatment, prolonging survival, and improving or preserving quality of life during illness.
For years, treatment of newly diagnosed glioblastoma has involved first removing as much of the tumor as possible surgically, followed by radiotherapy and temozolomide chemotherapy to prevent progression and spread. When surgery is impossible, radiotherapy and chemotherapy alone aim to prolong survival. Important advances have begun to emerge over the past 10 years. The benefit of concurrent temozolomide and radiotherapy, established in 2005, made a substantial contribution to survival. Researchers then identified VEGF-A as a factor contributing to new blood vessel formation by cancer cells (angiogenesis) and disease progression. Bevacizumab, which acts through this factor, was tested and found effective in recurrent and progressive cases. Studies then examined newly diagnosed cases, finding that bevacizumab alone was not effective.
A recent study in England investigated whether bevacizumab was effective when given concurrently with radiotherapy and temozolomide in newly diagnosed glioblastoma. It divided 921 newly diagnosed patients into 2 groups. One received bevacizumab with radiotherapy and temozolomide, and the other received only radiotherapy and temozolomide. There was no difference in overall survival. However, the bevacizumab group gained some benefit in delaying progression and maintaining quality of life and cognitive function. This group also needed less cortisone to reduce adverse effects of the disease and its treatments. Side effects were more frequent with bevacizumab, although not very serious.
In conclusion, in a disease this severe, reducing its effects and preserving quality of life are as important as prolonging survival. Bevacizumab may not prolong survival in newly diagnosed glioblastoma, but its contribution to maintaining quality of life is still an important advance. Nevertheless, many more tools and studies are needed to fight such an aggressive disease.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.